Kiniksa Announces FDA Approval of Arcalyst (rilonacept) for Recurrent Pericarditis

HAMILTON, Bermuda, March 18, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news